Researchers from The University of Texas Medical Branch at Galveston have developed the first vaccine for chikungunya fever made from an insect-specific virus that doesn’t have any effect on people, making the vaccine safe and effective. The newly developed vaccine quickly produces a strong immune defense and completely protects mice and nonhuman primates from disease when exposed to the chikungunya virus.
The findings are detailed in Nature Medicine.
“This vaccine offers efficient, safe and affordable protection against chikungunya and builds the foundation for using viruses that only infect insects to develop vaccines against other insect-borne diseases,” said UTMB professor Scott Weaver, senior author of this paper.
Chikungunya is a mosquito-borne virus that causes a disease characterized by fever and severe joint pain, often in hands and feet, and may include headache, muscle pain, joint swelling, or rash. Some patients will feel better within a week but many develop longer-term joint pain that can last up to years. Death is rare but can occur.
Traditionally, vaccine development involves tradeoffs between how quickly the vaccine works and safety. Live-attenuated vaccines that are made from weakened versions of a live pathogen typically offer rapid and durable immunity but reduced safety. On the other hand, the inability of inactivated vaccines to replicate enhances safety at the expense of effectiveness, often requiring several doses and boosters to work properly. There may be a risk of disease with both of these vaccine types, either from incomplete inactivation of the virus or from incomplete or unstable weakening of the live virus that is only recognized when rare vulnerable individuals develop disease.
To overcome these tradeoffs, the researchers used the Eilat virus as a vaccine platform since it only infects insects and has no impact on people. The UTMB researchers used an Eilat virus clone to design a hybrid virus-based vaccine containing chikungunya structural proteins.
The Eilat/Chikungunya vaccine was found to be structurally identical to natural chikungunya virus. The difference is that although the hybrid virus replicates very well in mosquito cells, it cannot replicate in mammals.
Within four days of a single dose, the Eilat/Chikungunya candidate vaccine induced neutralizing antibodies that lasted for more than 290 days. The antibodies provided complete protection against chikungunya in two different mouse models. In nonhuman primates, Eilat/Chikungunya elicited rapid and robust immunity – there was neither evidence of the virus in the blood nor signs of illness such as fever after chikungunya virus infection.
Receive an email update when we add a new CHIKUNGUNYA article.
The Latest on: Chikungunya vaccine
via Google News
The Latest on: Chikungunya vaccine
- Valneva Announces End of Phase 2 Meeting with the FDA for its Chikungunya Vaccine Candidateon January 7, 2020 at 8:45 am
announced today that an End Of Phase 2 (EOP2) meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on February 24, 2020 for its single-shot chikungunya vaccine candidate, ...
- Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potentialon December 31, 2019 at 2:17 am
Mayaro virus (MAYV) causes an acute febrile illness similar to that produced by chikungunya virus (CHIKV), an evolutionary ... A129 or IFNAR mice to wild-type CHIKV, two CHIKV vaccines, or a ...
- Kerala, Heal Thyselfon December 30, 2019 at 3:26 pm
Adding to the state’s concern is the increasing incidence of communicable diseases like chikungunya, dengue, leptospirosis ... The re-emergence of many diseases, including vaccine-preventable ones, ...
- Genetically modifying mosquitoes to prevent disease carries unknown riskson December 27, 2019 at 6:04 pm
In the absence of an effective vaccine for dengue fever, Zika fever, chikungunya and other mosquito-borne diseases, researchers have developed genetic strategies to reduce mosquito populations.
- Developing Chikungunya Virus Vaccines – Learning from the Immune Response towards the Infectionon December 17, 2019 at 8:53 am
Researchers at the Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines have been working in an international research partnership to investigate the immune response to the ...
- Chikungunya Virus and Prospects for a Vaccineon December 14, 2019 at 4:00 pm
Chikungunya virus (CHIKV) causes an acute febrile disease characterized ... Currently, there is no effective antiviral treatment for CHIKV infection or disease. However, there are several vaccine ...
- VALNEVA Reports Further Positive Results for Its Chikungunya Vaccine Candidateon December 13, 2019 at 7:55 am
Before it's here, it's on the Bloomberg Terminal.
- Developing Better Vaccines with Oracle Cloud Infrastructureon December 11, 2019 at 9:28 am
The findings, published in Science Advances, reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could ...
- Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidateon November 22, 2019 at 5:25 am
Abbey Jenkins, senior vice president and vaccines business unit head at Emergent BioSolutions, stated, “Emergent is pleased with the positive momentum and progress of our chikungunya vaccine ...
via Bing News